Clinical Trial

JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases

Name: JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases — clinical trial record (NCT06243159)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: JY231、ADs

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of refractory autoimmune diseases

Trial Details

NCT Number	NCT06243159
Lead Sponsor	Shanxi Bethune Hospital
Conditions	Autoimmune Diseases
Enrollment	20 participants
Start Date	2024-02-08
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-02-06